mass cytometry

Fluidigm said that Q3 mass cytometry product revenue more than doubled to $10.3 million from $5.1 million in the year-ago period.

The company gains global distribution rights for the Zurich team's histoCAT cytometry imaging software, which it will sell alongside its newly-launched Hyperion Imaging System.

The South San Francisco, California-based single-cell biology firm brought in $25.5 million compared to $29.0 million in the first quarter of 2016.

The researchers used mass cytometry to characterize dozens of markers in 3.5 million immune cells in samples from 73 clear cell renal cell carcinoma patients.

Combining PLA and mass cytometry, the method allows simultaneous measurement in the range of 40 to 50 RNAs and proteins in hundreds of thousands of cells.

Stanford researchers used Fluidigm's CyTOF instrument to explore links between the diversity of natural killer (NK) cell populations and HIV susceptibility.

According to the Piper Jaffray analysis, of the 54 total papers published using CyTOF technology, 25 of them, or 46 percent, were published in 2014.

NEW YORK (GenomeWeb) – Despite early softness in its recently acquired CyTOF business, Fluidigm officials this week reiterated the growing importance of proteomics in the firm's overall strategy.

Fluidigm said this week that it has agreed to acquire mass cytometry firm DVS Sciences for roughly $207.5 million in company common stock and cash.

A team led by researchers from Stanford University has developed a multi-omics approach for profiling individuals' immune systems.


Under a proposed spending bill, the US National Institutes of Health would see an additional $3 billion in funding.

Researchers from the University of Oxford and the University of Sydney sequenced numerous platypus genomes to study their population history.

Robert Redfield, the new pick to lead the US Centers for Disease Control and Prevention, has faced criticism for some of his work.

In Nature this week: sequenced genomes of five additional Neanderthals, and more.